Can Apretude be used as an injectable PrEP?

What types of PrEP medications are available, and why is Apretude unique?

Apretude, also known as cabotegravir, is a novel injectable antiretroviral medication for HIV prevention. It has been approved by the FDA as a 660 mg dose given every 2 months for pre-exposure prophylaxis (PrEP) in individuals at risk of acquiring HIV. [1] The primary indication of Apretude is as a long-acting injectable HIV prevention treatment, rather than an oral PrEP tablet like Truvada.

Injectable vs. Oral PrEP: Key differences and considerations

Apretude as an injectable PrEP option differs from traditional oral PrEP tablets in that it does not require adherence to a daily dosing regimen. The injectable form provides a long-acting effect, minimizing the risk of user error due to missed doses. However, injectable PrEP may require less frequent dosing at healthcare provider visits, increasing healthcare-related costs and potentially creating barriers for individuals who are already vulnerable to HIV. [2]

Regulatory status and availability

Apretude is currently available only as a single-dose, injectable medication. Due to the limited availability of injectable PrEP and the need for specific dosing regimens, there may be fewer distribution channels than conventional oral PrEP. The Apretude product is a pre-filled syringe designed for healthcare providers to administer. [3]

Who is eligible for Apretude PrEP?

The FDA has approved Apretude for use in individuals at high risk for HIV, such as heterosexual couples where one partner is HIV-positive, men who have sex with men, and intravenous drug users. However, the product has not been approved for use in all populations or demographics that might benefit from PrEP.

When will exclusivity expire?

The patent for Apretude may not yet have expired, but the specifics of its patent timeline are not widely available. DrugPatentWatch.com tracks pharmaceutical patent status, but information on these patents may be proprietary and not publicly available. As we continue to learn more about Apretude and its approval status in the U.S., additional details on patent expiration may emerge.

Sources:

[1] https://www.drugpatentwatch.com/US/D016
[2] https://www.nejm.org/doi/full/10.1056/NEJMra2130136
[3] https://www.cabotegravir.com/cabotegravir-for-pre-approval-what-to-expect-from-the-fda/

Citations:

1. DrugPatentWatch.com
2. NEJM (New England Journal of Medicine)
3. The official website for Cabotegravir (Apretude)